Alliances Through Integrity, Trust, Value Creation and Collaboration  
  • 1

    Tokyo-based Eisai Co., Ltd. Is a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders).

  • UCB

    UCB is a global biopharmaceutical company, with a focus on neurology and immunology. The key element of our evolution is to focus on the delivery of increased patient value. There is no such thing as an “average patient”. We want to use all the tools, channels and scientific advances at our disposal to develop a better understanding of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process. Rather than starting researching any new drug with the science alone, we want to better connect patients with science and science with patients. Better understanding the reality of patients living with neurological and immunological disorders will enable us to take a more holistic approach to care, ensuring that ultimately the right drug and the right care reaches the right patients in order for them to live the lives they choose.


    Allergan is a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The company is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team creating an unrivaled foundation for long-term growth.


    Kyowa Hakko Kirin is a research-based life sciences company with special strengths in biotechnology. We are opening up the path toward the development of new biologics, and developing new medicines to meet medical needs that are currently not being satisfied by existing pharmaceuticals.


    Abiogen Pharma is a privately owned specialist Italian pharmaceutical company focused on bone metabolism and some rare diseases. It is engaged in the research, the production of its own and external products, and the marketing of its own products.


    Sunovion Pharmaceuticals Europe, headquartered in London, is a wholly owned subsidiary of Sunovion Pharmaceuticals Inc. Additional information about Sunovion Pharmaceuticals Europe is available on the company’s website www.sunovion.eu. Sunovion Pharmaceuticals Inc. an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US. Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Additional information can be found on the company’s website www.sunovion.com.


    llumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are not only innovative, but flexible, and scalable, with industry-leading support and service. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe. Illumina has developed a comprehensive line of products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. Our broad portfolio of leading-edge sequencing and array-based solutions address a range of genomic complexity and throughput, enabling researchers to select the best solution for their scientific challenge.


    Veracyte is a diagnostics company pioneering the field of molecular cytology to improve patient outcomes and lower healthcare costs. We specifically target diseases that often require invasive procedures for an accurate diagnosis – diseases where many patients undergo costly interventions that ultimately prove unnecessary. We improve the accuracy of diagnosis at an earlier stage of patient care by deriving clinically actionable genomic information from cytology samples collected in an outpatient setting. Our tests are designed to answer a relevant clinical question and, when used at the optimal point in the diagnostic pathway, provide physicians with information that can significantly alter their decision‑making, enabling patients to potentially avoid unnecessary invasive and costly procedures.


    The brand Celia® was created at the same time as the company Celia - Laiterie de Craon in 1927 in Western France. A brand specialising in infant nutrition, it is well known to healthcare professionals. The brand Celia joined the Lactalis Group in 2007. The Group chose it as a strategic brand in infant nutrition for international development. The current range consists of powdered baby milk and infant cereals.


    GUARDANT HEALTH AMEA is a joint venture between SoftBank and Guardant Health, a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been used by more than 7,000 oncologists, over 60 biopharmaceutical companies and all 28 National Comprehensive Cancer Network Centers in the United States.


    A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of the Cologuard® and Oncotype DX® tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.

  • BeiGene

    BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 7,700 colleagues across five continents

  • 1